TABLE 1.

Performance of the IMFA with sera displaying different EBV-specific antibody profiles as determined by EIA

Serum group (no. of samples)EBV-specific antibody profileNo. (%) of samples with indicated IMFA result
PositiveWeakly positiveNegative
A (24)VCA IgG/IgM+, EBNA-1 IgG17 (70)4 (16)3 (14)
B (23)VCA IgG+/IgM+, EBNA-1 IgG17 (73)4 (17)2 (10)
C (10)VCA IgG/IgM, EBNA-1 IgG0 (0)0 (0)10 (100)
D (10)VCA IgG+/IgM, EBNA-1 IgG+0 (0)0 (0)10 (100)
E (20)VCA IgG+/IgM+, EBNA-1 IgG+2 (10)11 (55)7 (35)
Fa (15)1 (6)1 (6)13 (88)
  • a Sera from patients with a mononucleosis-like syndrome owing to CMV, parvovirus B19, or HHV-6. Ten sera lacked EBV-specific antibodies, four sera were VCA IgG+/IgM and EBNA-1 IgG+, and one serum sample was VCA IgG+/IgM and EBNA-1 IgG+.